Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759259 | 1.00 | ADORA2A (0.52) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL24758644 | 0.87 | ADORA2A (0.52) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL24758646 | 0.87 | ADORA2A (0.52) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL13394505 | 0.86 | ADORA2A (0.55) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL19441842 | 0.83 | ADORA2A (0.52) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL26647757 | 0.80 | KDM4E (0.35) | GRM4ADRB2 | |
| SCHEMBL26647762 | 0.80 | KDM4E (0.35) | GRM4ADRB2 | |
| SCHEMBL18713682 | 0.79 | ADORA2A (0.50) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL21240892 | 0.78 | ADORA2A (0.46) | ADORA2AADORA2BGRM4LSSQPCT | |
| SCHEMBL21239907 | 0.78 | ADORA2A (0.46) | ADORA2AADORA2BGRM4LSSQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294522-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2024-09-05 | — | — | US | disclosed |
| CN-117916239-A | 3-Substituted 1H-pyrrolo [2,3-b ] pyridines as GRK5 modulators | 利德探索中心股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294522-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | GRK5, GRK3, GRK4 | ADORA2A 862/4885ADORA2B 1037/4885GRM4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.